Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]

  • Awaiting development
  • GID-TA11945
  • Expected publication date: TBC

Status:
Awaiting development
Technology type:
Medicine
Decision:
Selected
Prioritisation programme:
Medicines evaluation
Rationale:
Criteria within the VPAG met as a significant licence extension. 
Process:
STA Standard

Project Team

Project lead
Danielle Lees

Timeline

Key events during the development of the guidance:

Date Update
22 January 2026 Awaiting development. Status change linked to topic prioritisation decision being set to Selected
22 January 2026 Topic prioritisation

For further information on our processes and methods, please see our CHTE processes and methods manual